Famotidine - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for famotidine and what is the scope of freedom to operate?
Famotidine
is the generic ingredient in fourteen branded drugs marketed by Ajanta Pharma Ltd, Akorn, Alkem Labs Ltd, Amneals Pharms, Annora Pharma, Carnegie, Epic Pharma Llc, Lupin Ltd, Micro Labs, Navinta Llc, Novel Labs Inc, Novitium Pharma, Unichem, Upsher Smith Labs, Salix Pharms, Apotex Inc, Apothecon, Fresenius Kabi Usa, Hikma, Hospira, Mylan Labs Ltd, Sagent, Zydus Pharms, Abbvie, Baxter Hlthcare, Merck, Merck Sharp Dohme, Perrigo, J And J Consumer Inc, Ucb Inc, Actavis Elizabeth, Alembic Pharms Ltd, Apotex, Ascent Pharms Inc, Aurobindo Pharma, Aurobindo Pharma Ltd, Carlsbad, Chartwell Rx, Contract Pharmacal, Dr Reddys Labs Ltd, Glenmark Pharms Inc, Graviti Pharms, Ivax Sub Teva Pharms, Mankind Pharma, Marksans Pharma, MSN, Mylan Pharms Inc, Natco Pharma, P And L, Perrigo R And D, Rising, Sandoz, Sun Pharm Inds Ltd, Sun Pharm Industries, Teva, Vkt Pharma, Watson Labs, Bausch, Horizon, Torrent, Endo Operations, and Teva Pharms Usa, and is included in ninety-eight NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.There are eighteen drug master file entries for famotidine. One hundred and forty-four suppliers are listed for this compound. There are five tentative approvals for this compound.
Summary for famotidine
US Patents: | 5 |
Tradenames: | 14 |
Applicants: | 62 |
NDAs: | 98 |
Drug Master File Entries: | 18 |
Finished Product Suppliers / Packagers: | 144 |
Raw Ingredient (Bulk) Api Vendors: | 83 |
Clinical Trials: | 118 |
Patent Applications: | 7,350 |
Drug Prices: | Drug price trends for famotidine |
Drug Sales Revenues: | Drug sales revenues for famotidine |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for famotidine |
What excipients (inactive ingredients) are in famotidine? | famotidine excipients list |
DailyMed Link: | famotidine at DailyMed |
Recent Clinical Trials for famotidine
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Miami | Phase 3 |
Celgene | Phase 1 |
Emory University | Phase 3 |
Generic filers with tentative approvals for FAMOTIDINE
Applicant | Application No. | Strength | Dosage Form |
⤷ Subscribe | ⤷ Subscribe | 10MG/ML | Injectable; Injection |
⤷ Subscribe | ⤷ Subscribe | 10MG/ML | Injectable; Injection |
⤷ Subscribe | ⤷ Subscribe | 10MG/ML | Injectable; Injection |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for famotidine
Drug Class | Histamine-2 Receptor Antagonist |
Mechanism of Action | Histamine H2 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for famotidine
Anatomical Therapeutic Chemical (ATC) Classes for famotidine
US Patents and Regulatory Information for famotidine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Labs Ltd | FAMOTIDINE PRESERVATIVE FREE | famotidine | INJECTABLE;INJECTION | 078642-001 | Jun 25, 2008 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Msn | FAMOTIDINE | famotidine | TABLET;ORAL | 217400-001 | Aug 6, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Merck Sharp Dohme | PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER | famotidine | INJECTABLE;INJECTION | 020249-001 | Feb 18, 1994 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Novitium Pharma | FAMOTIDINE | famotidine | FOR SUSPENSION;ORAL | 215043-001 | Apr 20, 2021 | AB | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-001 | Sep 24, 1998 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Hikma | FAMOTIDINE PRESERVATIVE FREE | famotidine | INJECTABLE;INJECTION | 075486-001 | Apr 16, 2001 | AP | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for famotidine
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020902-001 | Aug 5, 1999 | ⤷ Subscribe | ⤷ Subscribe |
J And J Consumer Inc | PEPCID AC | famotidine | TABLET, CHEWABLE;ORAL | 020801-001 | Sep 24, 1998 | ⤷ Subscribe | ⤷ Subscribe |
Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-002 | May 28, 1998 | ⤷ Subscribe | ⤷ Subscribe |
Merck | PEPCID RPD | famotidine | TABLET, ORALLY DISINTEGRATING;ORAL | 020752-001 | May 28, 1998 | ⤷ Subscribe | ⤷ Subscribe |
Salix Pharms | PEPCID | famotidine | FOR SUSPENSION;ORAL | 019527-001 | Feb 2, 1987 | ⤷ Subscribe | ⤷ Subscribe |
J And J Consumer Inc | PEPCID AC | famotidine | TABLET;ORAL | 020902-001 | Aug 5, 1999 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Famotidine Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.